human papillomavirus type 33 L1 protein

The human papillomavirus type 33 L1 protein is a recombinant viral structural protein that serves as a key antigenic component in prophylactic HPV vaccines, most notably the nonavalent vaccine (Gardasil 9). Produced using recombinant DNA technology in yeast (*Saccharomyces cerevisiae*), the L1 proteins self-assemble into virus-like particles (VLPs) that are morphologically similar to the native HPV capsid but lack the viral genome, rendering them non-infectious. Upon administration, these VLPs trigger a robust humoral immune response, leading to the production of high titers of neutralizing antibodies specific to HPV type 33. These antibodies prevent the virus from binding to and entering host epithelial cells, thereby providing protection against persistent infection and the development of associated pre-cancerous lesions, including cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), and vaginal intraepithelial neoplasia (VaIN). CHU Saint Pierre has been a significant contributor to the clinical development and evaluation of vaccines containing this protein.

Brand names

Gardasil 9Gardasil9Gardasil-9

Other names

HPV 33 L1 proteinHPV33 L1 proteinHPV-33 L1 proteinHPV 33 L1 VLPHPV33 L1 VLPHPV-33 L1 VLPhuman papillomavirus type 33 L1 capsid proteinrecombinant human papillomavirus type 33 L1 protein